{"pmid":32343807,"title":"The Elderly & COVID-19: Cocooning or Culling: - the choice is ours.","text":["The Elderly & COVID-19: Cocooning or Culling: - the choice is ours.","QJM","Donnelly, Sinead","32343807"],"journal":"QJM","authors":["Donnelly, Sinead"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343807","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/qjmed/hcaa145","weight":0,"_version_":1665351883836882945,"score":8.574329,"similar":[{"pmid":32319436,"title":"[The choices in CoViD-19's time.]","text":["[The choices in CoViD-19's time.]","In these times of insufficient resources for all there can be no shared decision-making, that is, a shared plan of care. Without attempting to subtly induce the patient to believe that it is the best decision for him. In the case of CoViD-19, we must rely on professionals: it is not the time for the anticipated treatment plan, for self-determination. Of course, we can always say \"no\"; but we hope that as soon as possible we will be able to take back all the freedoms that has just been conquered: that of end-of-life choices, after a process of sharing with the carers. But in this difficult moment someone can also feel a relief - that of the old paternalistic choices - that someone else decides for us.","Recenti Prog Med","Rinnenburger, Dagmar","32319436"],"abstract":["In these times of insufficient resources for all there can be no shared decision-making, that is, a shared plan of care. Without attempting to subtly induce the patient to believe that it is the best decision for him. In the case of CoViD-19, we must rely on professionals: it is not the time for the anticipated treatment plan, for self-determination. Of course, we can always say \"no\"; but we hope that as soon as possible we will be able to take back all the freedoms that has just been conquered: that of end-of-life choices, after a process of sharing with the carers. But in this difficult moment someone can also feel a relief - that of the old paternalistic choices - that someone else decides for us."],"journal":"Recenti Prog Med","authors":["Rinnenburger, Dagmar"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319436","week":"202017|Apr 20 - Apr 26","doi":"10.1701/3347.33177","source":"PubMed","weight":0,"_version_":1664815087860318208,"score":62.01203},{"pmid":32248724,"title":"Biologic therapy for psoriasis during the covid-19 outbreak is not a choice.","text":["Biologic therapy for psoriasis during the covid-19 outbreak is not a choice.","J Dermatolog Treat","Bardazzi, Federico","Loi, Camilla","Sacchelli, Lidia","Di Altobrando, Ambra","32248724"],"journal":"J Dermatolog Treat","authors":["Bardazzi, Federico","Loi, Camilla","Sacchelli, Lidia","Di Altobrando, Ambra"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32248724","week":"202015|Apr 06 - Apr 12","doi":"10.1080/09546634.2020.1749545","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352136221589505,"score":51.83062},{"pmid":32294321,"title":"Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","text":["Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5].","J Thromb Haemost","Hermans, C","Lambert, C","32294321"],"abstract":["Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5]."],"journal":"J Thromb Haemost","authors":["Hermans, C","Lambert, C"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294321","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14845","keywords":["covid-19","emicizumab","pandemic","clotting factor concentrates","direct oral anticoagulants","hemophilia"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636192764723200,"score":49.141212},{"pmid":32061198,"title":"[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].","text":["[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].","The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality.","Zhonghua Jie He He Hu Xi Za Zhi","Sun, M L","Yang, J M","Sun, Y P","Su, G H","32061198"],"abstract":["The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Sun, M L","Yang, J M","Sun, Y P","Su, G H"],"date":"2020-02-16T11:00:00Z","year":2020,"_id":"32061198","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0014","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664640875280465920,"score":49.141212},{"pmid":32231323,"title":"Cull, release or bring them home: Coronavirus crisis forces hard decisions for labs with animals.","text":["Cull, release or bring them home: Coronavirus crisis forces hard decisions for labs with animals.","Nature","Nowogrodzki, Anna","32231323"],"journal":"Nature","authors":["Nowogrodzki, Anna"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32231323","week":"202014|Mar 30 - Apr 05","doi":"10.1038/d41586-020-00964-y","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1664638455330635776,"score":48.58517}]}